Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Circio Holding ASA is a clinical-stage biotechnology company headquartered in Lysaker, Norway, specializing in the development of novel circular RNA (circRNA) therapeutics and immuno-oncology immunotherapies for treatment-resistant cancers and difficult-to-treat diseases. Formerly known as Targovax ASA until its rebranding in May 2023, the company pioneers proprietary platforms like circVec, a modular genetic cassette enabling efficient biogenesis of multifunctional circRNAs in human cells, and circAde, an engineered adenovirus delivery system targeting cancer cells. These technologies promise up to 15-fold enhanced protein expression and 70-fold greater durability compared to conventional mRNA systems, positioning circRNA as a potential gold standard for gene therapy, cell therapy, and nucleic acid medicines. Circio's pipeline includes the pan-RAS cancer vaccine TG01, in Phase 1/2 trials for multiple myeloma, pancreatic, lung cancer, and other indications through collaborations with institutions like Oslo University Hospital and Agenus, alongside oncolytic virus ONCOS-102. With approximately 9 employees and R&D centered at Sweden's Karolinska Institute, Circio plays a niche role in advancing next-generation oncology and genetic therapies within the biotechnology sector.
NOK 0.64
NOK 0.00 (-0.46%)
EOD Jul 1, 2026
ROIC dropped from -66.51% to -252.14%, capital efficiency is deteriorating. Negative free cash flow of -NOK 46M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
NOK 0.00
Net Income (TTM)
-NOK 46M
▼ -179.8% YoY
Op. Margin
—
ROIC
-252.14%
▼ -185.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-NOK 46M
▼ -12.5% YoY
Op. Cash Flow (TTM)
-NOK 46M
▼ -16.0% YoY
Net Debt
NOK 2M
Cash & Equiv.
NOK 6M
Continue Research
Circio Holding ASA (CRNA.XOSL)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Circio Holding ASA scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Circio Holding ASA scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -252.1% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh CRNA.XOSL's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.